Navigation Links
Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing
Date:11/12/2013

BURLINGTON, Mass., Nov. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while most of the biomarker-drug success stories are in oncology, biomarkers play a critical role in pharmaceutical development of chronic conditions, and their use in clinical trials of drugs outside of oncology is building. The Strategic Insights report entitled Driving Drug and Diagnostic R&D: The Influence of Biomarkers Beyond Oncology, finds that through biomarkers, upcoming chronic disease drugs will target new mechanisms of action, address niche subpopulations and fill the need for safer and more effective treatments. Biomarkers, when placed at the core of R&D programs, can reveal essential information about the drugs in development and/or the target populations.

According to the report, an analysis of ongoing clinical trials using biomarkers reveals a plethora of opportunities for drug R&D in a number of non-oncology therapy areas. Collectively, there are more clinical trials and deals over the last five years involving biomarkers for non-cancer indications than those focusing solely on cancer indications. For instance, all of AbbVie's trials using biomarkers are in non-cancer areas, as are more than half of all biomarker-focused trials sponsored by Merck, Roche, GlaxoSmithKline and Pfizer. While most active clinical trials involving biomarkers are in earlier phases, biomarkers in late-phase trials support label extension or evaluate long-term safety.

The report also explores how companies are capitalizing on the utility of biomarkers in the R&D programs in Alzheimer's disease, asthma, and type 2 diabetes.

"With the advances in biomarker research and in improved diagnostic imaging capabilities, the most notable impact of biomarker-involved drug development, outside of oncology, will be in central nervous system disorders," said Decision Resources Analyst Prachi Vora, M.P.H. "The incorporation of biomarker pathology in the inclusion criteria for a trial of Eli Lilly's solanezumab, an emerging therapy in Alzheimer's disease, is a key step toward mainstreaming biomarkers in CNS therapies."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
3. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
4. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
5. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
6. Spanish researchers design biomarkers for the detection of dengue and West Nile virus
7. NIH funds research to identify Parkinsons biomarkers
8. New AAN/ALS Association Clinical Fellow Will Pursue Immune Biomarkers
9. Epigenetic biomarkers may predict if a specific diet and exercise regimen will work
10. Novel biomarkers improve diagnosis in rheumatoid arthritis
11. Biomarkers Market: Epigenetic & MicroRNA Biomarkers Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will feature ... Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ... how to continue to feed a growing nation. At the same time, many of ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
(Date:10/5/2017)... , ... October 05, 2017 , ... LabRoots , ... scientists from around the world, is giving back to cancer research with a month-long ... , Now through October 31, shoppers can use promo code PinkRibbon to get ...
Breaking Biology Technology: